| During 2.3 years of lanreotide use, 15% of patients formed new gallstones, compared with 1% in untreated patients. |
| In most cases, these gallstones were multiple (>20) and small (≤3 mm). |
| About 50% of patients who developed gallstones during treatment experienced complications after discontinuation, while no complications occurred in untreated patients or patients with gallstones present before the start of treatment. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.